Establishment and characterization of a new human Burkitt's lymphoma cell line (WSU-BL).
A new human cell line, WSU-BL, was established from a malignant ascitic fluid occurring in a patient with Burkitt's lymphoma. The established line grows in a single-cell suspension with a doubling time of 19 hours and expresses L3 morphologic features by the French-American-British classification. Immunologic study revealed that WSU-BL cells express IgM-lambda both in the cytoplasm and on the surface and react with monoclonal antibodies to B-cell antigens (B1, B4, BL3, BL4, HLA-DR, and common acute lymphoblastic leukemia antigen [CALLA]). These cells are negative for T-cell and myeloid/monocyte antigens as well as Epstein-Barr virus nuclear antigen (EBNA). These results suggest that WSU-BL corresponds to an intermediate stage of B-cell differentiation. Both fresh tumor and WSU-BL cells had a hyperdiploid karyotype carrying the 8;14 chromosome translocation. Molecular studies showed that WSU-BL has a rearrangement of c-myc proto-oncogene and expresses c-myc RNA. Phorbol ester 12-0-tetradecanoylphorbol-13-acetate (TPA) and interferon-gamma (IFN-gamma) were able to induce several phenotypic changes on WSU-BL cells. Two-dimensional gel electrophoresis of total cellular protein showed that either TPA or IFN-gamma induced both the synthesis or loss of several proteins. Analysis of the protein patterns indicated that some proteins were uniquely responsive to either TPA or IFN-gamma and others were common to both. This cell line should be valuable for future studies of cell proliferation, differentiation, and oncogenesis concerning this neoplasm.
Mohamed
A N
AN
Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI.
Mohammad
R M
RM
Koop
B F
BF
al-Katib
A
A
D000328:Adult; D000943:Antigens, Differentiation / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis; D000954:Antigens, Surface / Q000032:analysis; D001202:Ascitic Fluid / Q000473:pathology*; D001402:B-Lymphocytes / Q000276:immunology; D002051:Burkitt Lymphoma / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D002454:Cell Differentiation; D002455:Cell Division; D003593:Cytoplasm / Q000276:immunology; D006801:Humans; D007075:Immunoglobulin M / Q000032:analysis; D007146:Immunoglobulin lambda-Chains / Q000032:analysis; D007371:Interferon-gamma / Q000494:pharmacology; D007621:Karyotyping; D008297:Male; D015260:Neprilysin; D000090063:Proto-Oncogene Mas; D011518:Proto-Oncogene Proteins / Q000235:genetics; D016271:Proto-Oncogene Proteins c-myc; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014178:Translocation, Genetic; D014407:Tumor Cells, Cultured
D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D007075:Immunoglobulin M; D007146:Immunoglobulin lambda-Chains; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D011518:Proto-Oncogene Proteins; D016271:Proto-Oncogene Proteins c-myc; D007371:Interferon-gamma; D015260:Neprilysin; D013755:Tetradecanoylphorbol Acetate